ReviewPharmaceutics2026
Surface-Engineered Phytochemical Nanomedicines for Postmenopausal Osteoporosis: Skeletal Targeting, Imaging-Supported Evaluation, and Therapeutic Performance.
Review in Pharmaceutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Postmenopausal osteoporosis (PMOP) is a metabolic bone disease driven by estrogen deficiency and a major contributor to fragility fractures, yet long-term use of current antiresorptive and anabolic agents remains constrained by tolerability and adherence. Plant-derived bioactive compounds-including flavonoids, isoflavones, curcuminoids, and stilbenes-show bone-protective activity in ovariectomized (OVX) models but share common delivery barriers: poor aqueous solubility, low oral bioavailability, rapid metabolic clearance, and limited skeletal targeting. Conventional nanonization improves systemic pharmacokinetics but cannot by itself address the spatial heterogeneity of skeletal target sites. This review focuses on surface-engineered phytochemical nanomedicines, in which mineral-affinity, cell-affinity, and pathology-responsive modules are introduced at the carrier interface to enhance bone-associated distribution, local retention, and microenvironment-responsive release. Organized around nanocarrier platforms, it summarizes cross-platform surface/interfacial engineering strategies and discusses how whole-body, ex vivo, and bone-section imaging can be combined with quantitative exposure assessment, micro-computed tomography (micro-CT), bone turnover markers, and histology to characterize carrier- or probe-associated distribution, spatial localization, and therapeutic performance, respectively. It then considers translational issues, including formulation reproducibility, ligand-density effects, model relevance, and long-term safety. The review aims to provide a framework for surface-engineered phytochemical strategies and a reference approach for multimodal, imaging-based evaluation of therapeutic outcomes.
Indexed as
Identifiers
42797338What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.